EUVIMEDEUVIMED entdecken
Crossref

Myeloid leukemia cells utilize branched chain keto acids to acquire intrinsic resistance to methotrexate

Naoki Tamura, Ayuna Hattori, Kenkyo Matsuura, Takashi Sakamoto iD, Hiroshi Arima, Akifumi Takaori-Kondo, Takahiro Ito iD

The Journal of Biochemistry · 04.11.2026

DOI: 10.1093/jb/mvag082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Biochemistry, online erschienen am 04.11.2026. Verfasst von Naoki Tamura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer reprograms cellular metabolism to support and accelerate malignant properties, which is known as cancer metabolism. The cancer metabolism has specific roles in acquiring drug resistance mechanisms in multiple types of cancer tissues. Myeloid leukemia cells deregulate branched chain amino acid (BCAA) metabolism to maintain their proliferation and undifferentiated status, but the contribution of this rewired pathway to drug resistance remains poorly understood. Here, we demonstrate that supplementation with branched chain keto acids (BCKAs), the transamination products of BCAAs, specifically attenuates methotrexate (MTX) toxicity in myeloid leukemia cells, whereas direct BCAA supplementation fails to provide a similar protective effect. Conversely, BCKA supplementation inhibits lymphoid leukemia cells, an effect potentially mediated by the activation of hypoxia-inducible factor 1α (HIF-1α). Gene expression analysis further suggests the involvement of activating transcription factor 5 (ATF5) in the BCKA-mediated rescue from MTX toxicity. Clinically, MTX serves as a standard-of-care treatment for lymphoid malignancies, whereas it typically exhibits limited efficacy against myeloid leukemia. Our results highlight a divergent, lineage-specific response to BCKAs, which may underlie metabolic basis for the intrinsic resistance of myeloid leukemia to MTX.

Autor:innen und Institutionen

  • Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Division of Cell Fate Dynamics and Therapeutics, Institute for Life and Medical Sciences (LiMe), Kyoto University, Kyoto, Japan.

ORCID-Profile: Takashi Sakamoto, Takahiro Ito

Zitieren

APA

Tamura, N., Hattori, A., Matsuura, K., Sakamoto, T., Arima, H., Takaori-Kondo, A., & Ito, T. (2026). Myeloid leukemia cells utilize branched chain keto acids to acquire intrinsic resistance to methotrexate. The Journal of Biochemistry. https://doi.org/10.1093/jb/mvag082

Vancouver

Tamura N, Hattori A, Matsuura K, Sakamoto T, Arima H, Takaori-Kondo A, et al. Myeloid leukemia cells utilize branched chain keto acids to acquire intrinsic resistance to methotrexate. The Journal of Biochemistry. 2026. doi:10.1093/jb/mvag082

BibTeX
@article{Tamura2026,
  author = {Tamura, Naoki and Hattori, Ayuna and Matsuura, Kenkyo and Sakamoto, Takashi and Arima, Hiroshi and Takaori-Kondo, Akifumi and Ito, Takahiro},
  title = {Myeloid leukemia cells utilize branched chain keto acids to acquire intrinsic resistance to methotrexate},
  journal = {The Journal of Biochemistry},
  year = {2026},
  doi = {10.1093/jb/mvag082}
}
Kostenlos starten →